20 completed, 10 terminated, 8 active not recruiting, 7 recruiting. 56 Phase 2, 7 Phase 1, 3 Phase 3.
Follow Thyroid Carcinoma, Anaplastic: new trials by email Literature Review of Thyroid Carcinoma, Anaplastic trials Research Report on Thyroid Carcinoma, Anaplastic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma | Phase 2 | Not yet recruiting | Northwestern University | 56 | 2027-05-05 | 2026-10-07 |
| Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer Cemiplimab, Zanzalintinib - Anaplastic Thyroid Cancer | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 12 | 2027-01-31 | 2026-10-14 |
| Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer Dabrafenib, Trametinib, Pembrolizumab - Anaplastic Thyroid Carcinoma, Thyroid Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 12 | 2026-12-31 | 2026-10-21 |
| Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer Selective coverage radiotherapy, comprehensive coverage radiotherapy - Thyroid Cancer | Phase 2 | Recruiting | Fudan University | 72 | 2026-08-12 | 2026-08-20 |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 - Peritoneal Mesothelioma, Gestational Trophoblastic Tumor | Phase 2 | Active not recruiting | Hospices Civils de Lyon | 27 | 2025-10-01 | 2026-06-25 |
| Sacituzumab govitEcan in THYroid Cancers Sacituzumab govitecan - Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer | Phase 2 | Recruiting | Grupo Espanol de Tumores Neuroendocrinos | 42 | 2024-09-13 | 2026-09-16 |
| Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer Pembrolizumab + Lenvatinib - Anaplastic Thyroid Cancer | Phase 2 | Recruiting | Saint Petersburg State University, Russia | 20 | 2024-03-25 | 2025-09-05 |
| Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy Dabrafenib + Trametinib - Anaplastic Thyroid Cancer | Phase 2 | Unknown | Saint Petersburg State University, Russia | 10 | 2024-03-25 | 2024-04-12 |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. Vemurafenib, Cobimetinib - Haematological Malignancy, Melanoma | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-01 | 2025-11-24 |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations Plixorafenib - Cancer Harboring BRAF Alterations, HGG | Phase 2 | Recruiting | Fore Biotherapeutics | 254 | 2023-02-21 | 2026-07-27 |
| NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) dabrafenib/trametinib - Anaplastic Thyroid Cancer | Phase 2 | Recruiting | Leiden University Medical Center | 20 | 2023-01-01 | 2023-10-12 |
| Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer Vudalimab - Locally Advanced Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma | Phase 2 | Suspended | Northwestern University | 54 | 2022-07-21 | 2026-08-14 |
| The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation HLX208 - Anaplastic Thyroid Cancer, ATC | Phase 1 / Phase 2 | Unknown | Shanghai Henlius Biotech | 25 | 2021-12-10 | 2023-08-21 |
| Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer Lenvatinib, Pembrolizumab - Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 25 | 2021-11-04 | 2026-08-10 |
| Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer Conventional Surgery, Dabrafenib, Intensity-Modulated Radiation Therapy - Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2021-06-24 | 2026-10-08 |
| Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2 - Metastatic Solid Tumor, Colorectal Cancer | Phase 1 / Phase 2 | Terminated | Hutchmed | 87 | 2021-03-05 | 2025-05-08 |
| Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib - Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2021-02-26 | 2026-05-20 |
| Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer Dabrafenib, Trametinib - Thyroid Gland Anaplastic Carcinoma | Phase 2 | Withdrawn | Saint Petersburg State University, Russia | 2021-01-22 | 2024-03-25 | |
| Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC) HX008 - Anaplastic Thyroid Cancer | Phase 2 | Unknown | Taizhou Hanzhong biomedical co. LTD | 66 | 2020-12-28 | 2020-10-05 |
Showing 20 of 56. Sign in to see all of them.
Thyroid Neoplasms (24) · Carcinoma, Medullary (9) · Thyroid Cancer, Papillary (9) · Head and Neck Neoplasms (8) · Adenocarcinoma, Follicular (6) · Glioma (5) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (4) · Neoplasms (4) · Ovarian Neoplasms (4) · Carcinoma, Hepatocellular (3) · Melanoma (3) · Multiple Myeloma (3) · Sarcoma (3)
Neoplasms, Glandular and Epithelial (56) · Carcinoma (55) · Neoplasms by Histologic Type (54) · Neoplasms (52) · Neoplasms by Site (32) · Endocrine Gland Neoplasms (28) · Endocrine System Diseases (28) · Thyroid Diseases (26) · Head and Neck Neoplasms (20) · Neoplasms, Germ Cell and Embryonal (17) · Neoplasms, Nerve Tissue (17) · Neuroectodermal Tumors (17) · Adenocarcinoma (14) · Neuroendocrine Tumors (12) · Adenocarcinoma, Papillary (9)
dabrafenib (8) · trametinib (8) · Paclitaxel (7) · pembrolizumab (6) · lenvatinib (5) · Doxorubicin (4) · Sorafenib (4) · Cisplatin (3) · Radiotherapy (3) · Radiotherapy, Intensity-Modulated (3) · fosbretabulin (3) · Bevacizumab (2) · Everolimus (2) · Filgrastim (2) · Magnetic Resonance Spectroscopy (2)
National Cancer Institute (NCI) (8) · M.D. Anderson Cancer Center (6) · Saint Petersburg State University, Russia (3) · Cancer Research UK (2) · Case Comprehensive Cancer Center (2) · Grupo Espanol de Tumores Neuroendocrinos (2) · Leiden University Medical Center (2) · Northwestern University (2) · Novartis Pharmaceuticals (2) · Alliance for Clinical Trials in Oncology (1) · Daiichi Sankyo (1) · Dana-Farber Cancer Institute (1) · Eisai Inc. (1) · Fore Biotherapeutics (1) · Fudan University (1)
United States (36) · China (5) · France (5) · Italy (5) · Netherlands (5) · Spain (5) · United Kingdom (5) · Canada (4) · Germany (4) · Russia (4) · Australia (3) · Japan (3) · Norway (3) · South Korea (3) · Sweden (3)
Ellen Kapiteijn, MD, PhD (2) · Maria E Cabanillas (2) · Mark Zafereo (2) · Panayiotis Savvides, MD (2) · Saad A Khan, MD (2) · Amir A Jazaeri (1) · Ashish Chintakuntlawar (1) · Barry L. Gause, MD (1) · Byung Chul Cho (1) · Eric J Sherman (1) · Eric Sherman, MD (1) · Francis P Worden, MD (1)
PMID 27240885, PMID 37816266, PMID 17985985, PMID 19265494, PMID 20851682, PMID 23113752, PMID 24050953, PMID 25092772, PMID 27169792, PMID 29072975, PMID 32179633, PMID 32364844, PMID 32538690, PMID 32818466, PMID 33720068, PMID 33961488, PMID 34838156, PMID 36108341, PMID 36681089, PMID 37059834, PMID 37219859, PMID 37934000, PMID 39446377, PMID 42673705
P30CA015083 (2), P30CA043703 (2), P30CA060553 (2), 2014 (1), 2015 (1), 2019 (1), 2023 (1), N01CM00099 (1), N01CM62205 (1), N01CM62206 (1), N01CM62207 (1), P30CA006516 (1), P30CA016058 (1), U01CA062502 (1), U01CA076576 (1)